Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Miscelaneous Frontpage Notices Previous | All Articles This Week | Next
This article originally posted 16 February, 2012 and appeared in  GLP-1 Receptor Agonist TherapyIssue 613

SPECIAL FEATURE: GLP-1 TEST YOUR KNOWLEDGE, PART 3

 

SPECIAL FEATURE: GLP-1 TEST YOUR KNOWLEDGE, Part 3

For previous questions in this special series, just follow this link to our Test Your Knowledge page.

Paul is a 53-year-old white male who has been diagnosed with type 2 diabetes mellitus (T2DM) for about 2 years. He is currently taking metformin 1000mg twice daily and glimepiride 4 mg once daily. Soon after diagnosis and beginning antihyperglycemics, Paul's glycosylated hemoglobin (A1c) showed improvement. His glycemic control worsened over subsequent years, and at a recent office visit his A1c was up to 7.8%. Paul has experienced several episodes of hypoglycemia in the last couple months. He has also continued to gain weight since diagnosis, with a current BMI of 35 kg/m2 and waist circumference of 43 inches. His most recent cholesterol panel was LDL 170 mg/dL, TG 200 mg/dL, HDL 45 mg/dL. He is currently taking simvastatin 20 mg daily.

Question 1: What is the goal A1c according to the AACE/ACE Consensus Statement on the treatment of T2DM? For the complete question and answer just follow this link.

 

 

Advertisement
Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 16 February, 2012 and appeared in  GLP-1 Receptor Agonist TherapyIssue 613

Past five issues: Issue 678 | Diabetes Clinical Mastery Series Issue 137 | Issue 677 | SGLT2 Special Edition Issue 2 | Diabetes Clinical Mastery Series Issue 136 |

 
Diabetes In Control Advertisers
 
Cast Your Vote
Should a person newly diagnosed with prediabetes be treated with medication along with lifestyle changes?

Navigate Diabetes In Control
Search Articles On Diabetes In Control